C79.51: Secondary malignant neoplasm of bone
C79.51 is a billable, specific ICD-10-CM code for secondary malignant neoplasm of bone. It is valid for submission on a claim.
Check C79.51 with the rest of the claim: free scrubberExcludes1 inherited from the categories above C79.51
A category’s note binds every code beneath it.
Written on C79.5: Secondary malignant neoplasm of bone and bone marrow
- secondary carcinoid tumors of bone (C7B.03)
Written on C79: Secondary malignant neoplasm of other and unspecified sites
- secondary carcinoid tumors (C7B.-)
- secondary neuroendocrine tumors (C7B.-)
Risk adjustment
C79.51 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 18 Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid2.341 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.
Medicare coverage
C79.51 is named in 60 Medicare coverage policies: 60 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52399Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars
- A52421Billing and Coding: Ibandronate Sodium
- A52453Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
Code history
Unchanged in every release from FY2024 to FY2027.